IMO-8400: Additional Phase I/II data

Data from 15 evaluable patients with relapsed or refractory Waldenstrom’s macroglobulinemia in an open-label, dose-escalation, U.S. Phase I/II trial showed that IMO-8400 for 24 weeks led to an ORR of ...